Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer
February 15 2022 - 7:00AM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric
medicine company commercializing the CellFX® System powered by
Nano-Pulse Stimulation™ (NPS™) technology, today announced the
appointment of Kevin Danahy to the newly created role of Chief
Commercial Officer.
“As an industry veteran, Kevin has a proven track record of
building exceptional commercial teams and implementing strategies
to drive market penetration and significant growth with new medical
technologies across a variety of medical disciplines,” said Darrin
Uecker, President and CEO of Pulse Biosciences. “His broad
experience selling complex novel platform technologies makes Kevin
uniquely qualified to take on the Chief Commercial Officer role at
Pulse Biosciences as we grow the CellFX System business in
dermatology and expand into new applications and markets. We are
delighted to welcome Kevin to the Pulse Biosciences team and look
forward to the impact he will have on expanding the commercial
footprint for the CellFX System.”
Mr. Danahy has more than 20 years of senior management
experience building and managing strategic commercial organizations
for medical technology companies. Most recently, Mr. Danahy served
as President of Solmetex, driving revenue growth for the company
through the implementation of innovative and scalable solutions,
while overseeing strategy, sales, marketing, operations,
engineering, and service efforts. Previously, at Zimmer Biomet, Mr.
Danahy held roles of increasing responsibility, most recently as
Vice President of Global Emerging Technologies and Specialty Sales.
Before his time at Zimmer, Mr. Danahy served as Sr. Director at
Intuitive Surgical, where he successfully transformed the sales
leadership training program. Early in his career, he served in
commercial leadership roles at both Medtronic and Johnson &
Johnson. Mr. Danahy received a Master’s of Science from Tufts
University.
“It is a privilege to take on the role of CCO at such a
transformational time for Pulse Biosciences. This team has done an
incredible job developing a novel technology platform at the
intersection of healthcare and technology that can address the
needs of a broad patient population,” said Kevin Danahy, Chief
Commercial Officer of Pulse Biosciences. “I believe Pulse
Bioscience’s proprietary NPS technology delivered by the CellFX
System has the power to improve the lives of patients across
aesthetics, dermatology and other medical specialties, and I’m
excited to be a part of the next phase in the Company’s
growth.”
Inducement Awards
In connection with his appointment as Chief Commercial Officer,
Mr. Danahy has been granted stock options to purchase an aggregate
of 300,000 shares of Company common stock. The Company’s
independent compensation committee approved the award as an
inducement material to Mr. Danahy’s employment in accordance with
Nasdaq Listing Rule 5635(c)(4). The stock options will have an
exercise price per share equal to the closing price of the
Company’s common stock on February 14, 2022 and will be subject to
a mix of time-based and performance-based vesting criteria over
four years, subject to Mr. Danahy’s continued employment with Pulse
Biosciences.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nano-Pulse Stimulation technology delivers nano-second pulses of
electrical energy to non-thermally clear cells while sparing
adjacent non-cellular tissue. The CellFX® System is the first
commercial product to harness the distinctive advantages of NPS
technology to treat a variety of applications for which an optimal
solution remains unfulfilled. The initial commercial use of the
CellFX System is to address a range of dermatologic conditions that
share high demand among patients and practitioners for improved
dermatologic outcomes. Designed as a multi-application platform,
the CellFX System offers customer value with a utilization-based
revenue model. Visit pulsebiosciences.com to learn more.
To stay informed about the CellFX System, please visit
CellFX.com and sign-up for updates.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the
stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
Forward Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to Pulse Biosciences’ expectations regarding
the commercialization of the CellFX System to drive Company growth,
statements relating to the effectiveness of the Company’s NPS
technology and the CellFX System to positively impact the lives of
patients across aesthetics, dermatology and other medical
specialties, statements relating to the Company’s pipeline of
product candidates, statements relating to market opportunities and
commercial launch plans, including statements about the Company’s
ability to pursue applications for NPS technology outside of
dermatology, expand CellFX System applications and markets, and
address the needs of a broad patient population , and about other
future events. Words such as “may,” “will,” “could,” “would,”
“should,” “anticipate,” “predict,” “potential,” “continue,”
“expects,” “intends,” “plans,” “projects,” “believes,” “estimates,”
and other similar or related expressions are used to identify these
forward-looking statements, although not all forward-looking
statements contain these words. You should not place undue reliance
on forward-looking statements because they involve known and
unknown risks, uncertainties, and assumptions that are difficult or
impossible to predict and, in some cases, beyond Pulse Biosciences’
control. Actual results may differ materially from those in the
forward-looking statements as a result of a number of factors,
including those described in Pulse Biosciences’ filings with the
Securities and Exchange Commission. Pulse Biosciences undertakes no
obligation to revise or update information in this press release to
reflect events or circumstances in the future, even if new
information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220215005490/en/
Investors: Pulse Biosciences Sandra Gardiner, EVP and CFO
510.241.1077 IR@pulsebiosciences.com or Gilmartin Group Philip Trip
Taylor 415.937.5406 philip@gilmartinir.com
Media: Tosk Communications Nadine D. Tosk 504.453.8344
nadinepr@gmail.com or press@pulsebiosciences.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2024 to May 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From May 2023 to May 2024